John Neylan

Shares of Keryx Biopharmaceuticals (NASDAQ: KERX), a biopharmaceutical company that focuses on the treatment of renal diseases, gained more than 20 percent early Tuesday morning. Keryx Biopharmaceuticals announced positive top-line results from its pivotal Phase 3 study of ferric citrate for the...